



ASX RELEASE (9 DECEMBER 2021)

Completion of Capital Raising

Epsilon Healthcare Limited (ASX:EPN) (Epsilon or the Company) is pleased to advise that the Company has completed a capital raising of \$2.9 million (before costs) to professional and sophisticated investors, led by CPS Capital (the Placement).

The Placement has been completed at \$0.09 per share, being a 14.6% discount to the 10 day Volume Weighted Average Price (VWAP) of the Company's securities on ASX, resulting in the issue of 32.22 million fully paid ordinary shares (the Placement Shares).

The Company is pleased to have received strong support from both new and existing sophisticated and professional investors exempt from disclosure under section 708 of the *Corporations Act 2001* (Cth).

Subject to shareholder approval, Placement participants will also receive one new option for every two shares subscribed for in the Placement with those options being each exercisable at \$0.15 and expiring three years from their issue following shareholder approval (the Placement Options). Subject to shareholder approval, CPS Capital (or their nominee), as the Lead Manager will also receive an allocation of Options on a one new Placement Option for every two shares issued basis – being 16.11 million Placement Options.

The Company will apply the funds raised towards further growth initiatives including expanding production capabilities at the Southport Facility, expanding our Tetra Health clinics network, and for additional working capital.

Additionally, subject to shareholder, regulatory, and any ASX approval required, the Company will seek that the Placement Options be quoted on ASX. The Company expects to seek such shareholder approval at the earlier of the 2022 Annual General Meeting or at any general meeting of the Company convened prior.

The Company expects settlement to occur on 15 December 2021, with Placement Shares to be issued on 16 December 2021.

The issue of the Placement Shares will be made under both ASX Listing Rule 7.1 (12,951,528 FPO) and 7.1A (19,270,694 FPO), with the issue of any Placement Options not being made without shareholder approval.

ENDS

ASX release authorised by the EPN Board of Directors.

For further information, please contact:



Jarrold White

Group Chief Executive Officer
e: ceo@epsilonhc.com

Sonny Didugu

Group Chief Operating Officer
e: coo@epsilonhc.com

Steven Xu

Non-Exec Chairman
e: corporate@epsilonhc.com

Investor & Media Enquiries:

Rod Hinchcliffe

Media and Capital Partners
p: +61 412 277 377
e: rod.hinchcliffe@mcpartners.com.au

Melissa Hamilton

Media and Capital Partners
p: +61 417 750 374
e: melissa.hamilton@mcpartners.com.au

Epsilon Healthcare Limited (ASX: EPN) – epsilonhealthcare.com.au

Epsilon Healthcare (ASX:EPN) is a diversified global healthcare and pharmaceuticals company. EPN owns a number of medicinal cannabis assets including the largest GMP cannabis manufacturing facility in the Southern Hemisphere, the Tetra Health clinic group, and the Medimar Platform. EPN additionally operates a turn-key cannabis cultivation solutions provider based in Vancouver, Canada.